Homepage Top Section2

Givlaari, an injection for subcutaneous use, is an RNAi therapeutic that targets aminolevulinic acid synthase 1 (ALAS1) to treat AHP, an ultra-rare condition where patients experience severe abdominal

Forty Seven is engaged in the development of novel checkpoint therapies to stimulate macrophages for the treatment of cancer. The deal is expected to strengthen Gilead’s immuno-oncology research

Last September, the company secured approval from the US Food and Drug Administration (FDA) for nintedanib to slow the rate of decline in pulmonary function in adults living

The regulator has accepted the application for the use of once-daily and single-inhaler triple therapy, Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol or FF/UMEC/VI) to treat asthma in adults. Trelegy Ellipta

LXE408 was discovered at Novartis with the financial backing of the Wellcome Trust. According to Novartis, more than a billion people across the world are at risk of

Under a strategic collaboration agreement, the companies will involve in the discovery, development and commercialisation of novel Bicycle Therapeutics-based immuno-oncology therapies. The deal allows Bicycle to explore its

Under the research collaboration, the companies will evaluate Clover’s protein-based coronavirus vaccine candidate (COVID-19 S-Trimer) with GSK’s pandemic adjuvant system. GSK’s pandemic adjuvant system will help further assess

Claimed to be the first FDA-approved intravenous (IV) treatment for migraine prevention, the Vyepti will be available from April and the recommended dose is 100mg for every three

As per terms of the deal, Immatics will secure an upfront payment of up to $50m from GSK for two initial programmes. Immatics has an option to secure